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is recommended that a single trial inhalation using epinephrine 
or albuterol is to be considered on an individual basis.
Nebulized racemic epinephrine demonstrates better short-
term improvement in pulmonary physiology. Combined treatment 
of systemic glucocorticoids (dexamethasone) and bronchodilators 
(epinephrine) may significantly reduce hospital admissions.
It is recommended the infant be suctioned, when clinically in-
dicated before feedings, as needed, prior to each inhalation therapy 
and normal saline nose drops may be used prior to suctioning. 
Current guidelines do not recommend routine chest physiotherapy 
in the management of bronchiolitis.
Infants with this severe disease may need supportive care for 
respiratory failure and dehydration, such as mechanical ventilation 
and supplemental fluid therapy. Treatment for severe bronchiolitis 
may include: humidified oxygen therapy, chest physical therapy, 
bronchodilator medications: Ventolin, Salbutamol, Epinephrine 
(Adrenalin), anti-viral medication from bronchiolitis: ribavirin, 
palivizumab, antibiotics for associated otitis media, suspected 
bacterial pneumonia, and mechanical ventilation.
It is recommended that the family be educated on the following 
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Cystic fibrosis (CF) is a life-shortening genetic disease cha-
racterized by variability in the age of death. This is largely due to 
variability in the rate of progression of lung disease, the primary 
cause of mortality. In most patients with cystic fibrosis (CF) life 
expectancy is limited due to a progressive loss of functional lung 
tissue. 80% of premature deaths continue to result directly or 
indirectly from loss of lung function. 
The factors associated with an increased risk of lung disease 
progression are: young age, high lung function, being of the fe-
male sex, certain CFTR genotypes, pancreatic insufficiency, poor 
nutritional status, lower socioeconomic status, respiratory viral 
infections, and infection of Pseudomonas aeruginosa or Burkhol-
deria cepacia.
 Virtually all patients with CF are chronically infected with one 
or more bacterial species, and the inflammatory response to infec-
tion appears to be more intense in patients with CF. Early infection 
of CF in the airways is mostly caused by Staphylococcus aureus and 
Haemophilus influenza, than from P. aeruginosa or other gram 
negative stains. Recent studies, especially those following patients 
diagnosed by neonatal screening, have shown that infection of P. 
aeruginosa usually occurs at very young age. Positive antibody 
response to P. aeruginosa was found in children, with the mean age 
of 15 months, about 12 months before first cultures were positive. 
Also in young, non-sputum producing children it was found that 
throat swabs frequently showed positive cultures for P. aeruginosa. 
Chronic infection is prevalent in about 80% of all patients with 
CF. In patients with chronic infection and alginate-coated mucous 
strains of Ps. aeruginosa, eradication is nearly impossible. CF and 
Ps. aeruginosa, an unfavorable relationship, can be explained by the 
possibility of CFTR acting as a specific receptor for Ps. aeruginosa. 
CFTR may influence bacterial adherence to epithelial cells. The 
“overproduction” of pro-inflammatory cytokines and significantly 
lower levels of the anti-inflammatory cytokine IL-10, which in-
hibits the production of pro-inflammatory cytokines, results in 
excessive and persistent inflammation in the CF airways. As a 
result, lung functioning deteriorates more rapidly in Ps. aerugi-
nosa-positive CF patients compared with Ps. aeruginosa-negative 
CF patients. Patients with cystic fibrosis are often colonized with 
bacteria other than PA, causing bronco-pulmonary infections that 
lead to the deterioration of lung functioning such as: Burkholderia 
cepacia complex, Achromobacter xylosoxidans and Stenotrophomo-
nas maltophilia. Patients chronically infected with S. maltophilia 
are cable of rising a specific antibody response against this bacteria 
associated with worsening lung function. Chronic infection of S. 
maltophilia is correlated with a decline in lung functioning, but this 
decline was already present prior to the chronic infection, where 
the high prevalence of Aspergillus and ABPA and NTM may have 
contributed a role in this result. 
Staphylococcus aureus (S. aureus) is one of the earliest bacteria 
detected in infants. Treatment with anti-staphylococcal agents 
reduces the infection rate of MSSA but may lead to a higher rate 
of infection of Ps. aeruginosa. S. aureus which isolates harbor to 
a multitude of virulence factors, overlapping to a large degree in 
MSSA and MRSA. To date there are no conclusive studies demon-
strating that the early aggressive treatment of MRSA respiratory 
infection can prevent chronic infection or if this approach ulti-
mately improves outcomes.
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topics regarding the care of a child with bronchiolitis: to call their 
primary care provider if the following signs of worsening clinical 
status are observed: increasing respiratory rate and/or work of 
breathing as indicated by use of the accessory muscle, inability to 
maintain adequate hydration, or worsening general appearance.
Therapies NOT Routinely Recommended:
It is recommended that scheduled or serial inhalation thera-
pies not be used routinely nor repeated if there is no measured 
improvement in the clinical outcome after a trial inhalation. 
Hypertonic saline inhalations are not to be given for the routine 
treatment of bronchiolitis due to inconsistent evidence regarding 
its effectiveness. It is recommended at this time that the following 
drugs not be used in the treatment of bronchiolitis: antibodies 
(immunoglobulins), Montelukast, Recombinant human deoxy-
ribonuclease (rhDNase), antihistamines, oral decongestants, and 
nasal vasoconstrictors. Antibiotics are not recommended unless 
bacterial infection is suggested (e.g., toxic appearance, hyperpy-
rexia, consolidation or focal lobar infiltrates on chest radiograph, 
leukocytosis, positive bacterial cultures).
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